Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin (ABBV-399) in Advanced Solid Tumors
NCT02099058Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
Phase 1, open-label trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events up to 24 Months, Recommended Phase 2 Dose up to 24 Months and 4 more. Started Jan 2014; status: active, not recruiting.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02099058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099058.